Evidence map›Paper›PMID 31601975›Full record

ArticleScientific reports2019

Neo-antigen specific T cell responses indicate the presence of metastases before imaging.

V S Fear, C A Forbes, J Chee, S Ma, S Neeve, L Celliers, S A Fisher, I Dick, J Creaney, B W S Robinson

Abstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

V S FearNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia. vanessa.fear@telethonkids.org.au.ORCID http://orcid.org/0000-0001-8363-6685
C A ForbesNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.
J CheeNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.ORCID http://orcid.org/0000-0002-7986-2708
S MaNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.
S NeeveNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.
L CelliersAustralian Cancer Research Foundation, Cancer Imaging Facility, Perth, Western Australia, 6009, Australia.
S A FisherNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.ORCID http://orcid.org/0000-0003-1551-5579
I DickNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.ORCID http://orcid.org/0000-0003-1902-9033
J CreaneyNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.
B W S RobinsonNational Centre for Asbestos Related Diseases (NCARD), Lv5 QQ Block (M503), QEII Medical Centre, The University of Western Australia, Perth, Western Australia, 6009, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) causes 19% of all Australian cancer deaths, with a 5-year survival post-resection of around 60%. Post-operative recurrence is due to metastases that were undetectable pre-operatively, or growth of microscopic locoregional residual disease. However, post-operative imaging modalities typically only detect more advanced tumours; where PET-CT has a detection limit of 6-7 mm. Detection of small deposits of lung metastatic disease is of importance in order to facilitate early and potentially more effective treatment. In this study, in a murine model of lung metastatic disease, we explore whether neo-antigen specific T cells are a sensitive marker for the detection of lung cancer after primary tumour resection. We determine lung metastatic disease by histology, and then compare detection by PET-CT and neo-antigen specific T cell frequency. Detection of lung metastatic disease within the histology positive group by PET-CT and neo-antigen specific T cell frequency were 22.9% and 92.2%, respectively. Notably, neo-antigen specific T cells in the lung draining lymph node were indicative of metastatic disease (82.8 ± 12.9 spots/10

Indexed as

AgedAnimalsAntigens, NeoplasmCarcinoma, Non-Small-Cell LungCell Line, TumorDisease Models, AnimalEnzyme-Linked Immunospot AssayFemaleHumansLungLung NeoplasmsLymphatic MetastasisLymph NodesLymphocytes, Tumor-InfiltratingMiceMiddle AgedAntigens, Neoplasm

Identifiers

PMID31601975
PMCPMC6787183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.